Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Amy Schulman
AddedFeb 13, 2024
UpdatedMay 31, 2026
Amy Schulman

Amy Schulman

Board Member, Alnylam Pharmaceuticals aln

CrunchbaseThe Org

Amy Schulman's Career

Alnylam Pharmaceuticals aln
Alnylam Pharmaceuticals aln

Cambridge, MA, US

Board Member· Board
SQZ Biotechnologies
SQZ Biotechnologies

Watertown, MA, US

Board Member· Board
Kallyope
Kallyope

New York City, NY, US

Board Member· Board
Lyndra
Lyndra

Watertown, MA, US

Board Member· Board
Thirty Madison
Thirty Madison

New York City, NY, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Amy Schulman's Career

Alnylam Pharmaceuticals aln
Alnylam Pharmaceuticals aln
Public$3.9B2k2002Cambridge, MA, US
Board Member· Board

Leadership at Alnylam Pharmaceuticals aln

Phillip SharpPhillip SharpBoard Member
Yvonne GreenstreetYvonne GreenstreetCEO
John ClarkeJohn ClarkeBoard Member
Paul SchimmelPaul SchimmelCo-Founder
YVONNE GREENSTREETYVONNE GREENSTREETCEO
Colleen ReitanColleen ReitanBoard Member

Similar to Alnylam Pharmaceuticals aln

Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
Silence TherapeuticsSilence TherapeuticsLondon, Greater London, GBRNA Therapeuticsest. 1994Silence TherapeuticsLondon, Greater London, GB · est. 1994

UK biotech co. discovering molecules with RNA tech to target genes in diseases with unmet needs.

Public · $248.7M120
Atalanta TherapeuticsAtalanta TherapeuticsBoston, MA, USRNA Therapiesest. 2018Atalanta TherapeuticsBoston, MA, US · est. 2018

Atalanta Therapeutics: A biotech pioneer in RNA interference-based treatments for neurodegenerative diseases.

Series A · $110M62
SQZ Biotechnologies
SQZ Biotechnologies
Public$229.8M1132013Watertown, MA, US
Board Member· Board

Leadership at SQZ Biotechnologies

Garry NicholsonGarry NicholsonBoard Member
Zafi AvnurZafi AvnurBoard Member
Bob LangerBob LangerCo-Founder
Eric MoessingerEric MoessingerBoard Member
Klavs JensenKlavs JensenCo-Founder
Marc EliaMarc EliaBoard Member
Kallyope
Kallyope
Series A$487.2M1082015New York City, NY, US
Board Member· Board

Leadership at Kallyope

Jeff GoaterJeff GoaterBoard Member
Charles ZukerCharles ZukerCo-Founder
Richard AxelRichard AxelCo-Founder
Peter HechtPeter HechtBoard Member
Bill RieflinBill RieflinBoard Member
Jay GaleotaJay GaleotaBoard Member

Similar to Kallyope

Bloom ScienceBloom ScienceSan Diego, CA, USDrugs, Therapeuticsest. 2018Bloom ScienceSan Diego, CA, US · est. 2018

Bloom Science: A biotech firm innovating gut-brain axis targeted drugs for neurology, immunology, and oncology.

Series A · $12M17
EnterinEnterinPhiladelphia, PA, USBiomedical Products, Therapiesest. 2016EnterinPhiladelphia, PA, US · est. 2016

Enterin, Inc.: Global provider of innovative biomedical products and therapies for neurodegenerative diseases.

Series A · $81.6M26
Axial TherapeuticsAxial TherapeuticsWoburn, MA, USTherapeuticsest. 2016Axial TherapeuticsWoburn, MA, US · est. 2016

Axial Biotherapeutics develops gut-restricted small molecules for treating central nervous system disorders.

Series C · $110.9M29
Lyndra
Lyndra

Watertown, MA, US

Board Member· Board
Thirty Madison
Thirty Madison
Series C$228.3M4752017New York City, NY, US
Board Member· Board

Leadership at Thirty Madison

Demetri KaragasDemetri KaragasCo-Founder
Steven GutentagSteven GutentagCo-Founder
Jason StofferJason StofferBoard Member
Randy ScottRandy ScottBoard Member

Amy Schulman's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Amy Schulman

Daniel LynchDaniel LynchBoard Member · Blueprint MedicinesDavid GrayzelDavid GrayzelBoard Member · Affinia TherapeuticsRichard LowenthalRichard LowenthalCo-Founder & CEO · ARS PharmaceuticalsPaula SoteropoulosPaula SoteropoulosBoard Member · EnsomaLinda GraisLinda GraisBoard Member · Zosano PharmaDavid S. TierneyDavid S. TierneyBoard Member · Catalyst Pharmaceuticals